Compass Therapeutics Inc. Common Stock

Compass Therapeutics Inc. a clinical-stage oncology-focused biopharmaceutical company engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009 a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1 and vascular endothelial growth factor A signaling pathways which are critical to angiogenesis and tumor vascularization; and CTX-471 an IgG4 monoclonal antibody that is an agonist of CD137 a key co-stimulatory receptor on immune cells. It also develops CTX-8371 a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics Inc. was founded in 2014 and is headquartered in Boston Massachusetts.